Abstract

Objective: The aim of the study was to assess the accuracy of N-terminal probrain natriuretic peptide (NT-proBNP) to predict mortality or detect acute ischemia in patients with coronary artery disease (CAD). Methods: This study included 1,552 patients with stable (n = 1,059) or unstable (n = 493) CAD undergoing percutaneous coronary intervention. NT-proBNP was measured before percutaneous coronary intervention. The primary endpoint of the study was mortality. Patients were followed for 3.6 years. Results: There were 171 deaths (11%) during follow-up. In the entire group of patients, NT-proBNP had the best accuracy to predict mortality (area under receiver operating characteristic curve 0.76, 95% CI 0.72–0.80). In patients without congestive heart failure (n = 760) there were 46 deaths (6%). The area under receiver operating characteristic curve of NT-proBNP was reduced to 0.70 (95% CI 0.63–0.79) which was not better than the area under curve of age (p = 0.981) or C-reactive protein (p = 0.082) regarding mortality. NT-proBNP showed limited power to detect patients with acute ischemia (area under curve 0.63, 95% CI 0.60–0.66) among consecutive patients with stable and unstable CAD. Conclusions: NT-proBNP has a moderate accuracy to predict mortality and does not assist in the diagnosis of acute myocardial ischemia in patients with CAD.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call